116 related articles for article (PubMed ID: 3264332)
1. [An application of leukapheresis for a clinical trial of adoptive immunotherapy].
Ikawa T; Eura M; Maehara T; Arishima S; Fukushima M; Fukiage T; On N; Ishikawa T
Nihon Jibiinkoka Gakkai Kaiho; 1988 Sep; 91(9):1353-7. PubMed ID: 3264332
[No Abstract] [Full Text] [Related]
2. [Adoptive immunotherapy by intra-arterial infusion of ATLAK or Allo-TLAK cells in patients with head and neck cancer].
Ikawa T; Eura M; Fukiage T; Murakami H; Yamasaki S; Fukuda K; Fukushima M; Arishima S; Maehara T; Ishikawa T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1438-47. PubMed ID: 2786378
[TBL] [Abstract][Full Text] [Related]
3. [Adoptive immunotherapy of malignant diseases with LAK cells].
Kimoto Y; Tanji Y; Tanaka T; Taguchi T
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 1):687-92. PubMed ID: 3493732
[TBL] [Abstract][Full Text] [Related]
4. [LAK-adoptive immunotherapy with cytapheresis].
Urushizaki I
Rinsho Ketsueki; 1988 Nov; 29(11):1965-72. PubMed ID: 3266257
[No Abstract] [Full Text] [Related]
5. The current status and future applications of interleukin 2- and adoptive immunotherapy in cancer treatment.
Simpson C; Seipp CA; Rosenberg SA
Semin Oncol Nurs; 1988 May; 4(2):132-41. PubMed ID: 3287538
[No Abstract] [Full Text] [Related]
6. Adoptive immunotherapy for head and neck cancer with killer cells induced by stimulation with autologous or allogeneic tumour cells and recombinant interleukin-2.
Ishikawa T; Ikawa T; Eura M; Fukiage T; Masuyama K
Acta Otolaryngol; 1989; 107(5-6):346-51. PubMed ID: 2787951
[TBL] [Abstract][Full Text] [Related]
7. [Study of head and neck cancer treatment by administration of autologous cytotoxic lymphocyte induced by stimulation with tumor cell--effect of adoptive immunotherapy by intra arterial infusion of killer cells stimulated by allogeneic tumor in patients with lingual and maxillary carcinoma].
Ishikawa T; Ikawa T; Eura M; Fukiage T; Arishima S; Yamasaki S; Kitao K; Uno K; Won N; Ohkubo Y
Nihon Jibiinkoka Gakkai Kaiho; 1988 Dec; 91(12):2082-8. PubMed ID: 3266243
[No Abstract] [Full Text] [Related]
8. [Adoptive immunotherapy using cytapheresis].
Takago H; Sasakawa H; Kanizawa Y; Nojiri H; Ueno Y
Rinsho Ketsueki; 1986 Jul; 27(7):1242-6. PubMed ID: 3491233
[No Abstract] [Full Text] [Related]
9. Adoptive immunotherapy in gastrointestine malignancies using interleukin-2. Current results and future prospects.
Marshall GD
Acta Chir Scand Suppl; 1989; 549():71-4. PubMed ID: 2784605
[No Abstract] [Full Text] [Related]
10. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2.
Merchant RE; Grant AJ; Merchant LH; Young HF
Cancer; 1988 Aug; 62(4):665-71. PubMed ID: 2840186
[TBL] [Abstract][Full Text] [Related]
11. [Experimental approach to immunotherapy in head and neck malignant tumors--antitumor efficacy by lymphokine activated human peripheral blood lymphocytes].
Takeda T
Nihon Jibiinkoka Gakkai Kaiho; 1986 Jun; 89(6):744-53. PubMed ID: 3489826
[No Abstract] [Full Text] [Related]
12. Therapy of cancer using the adoptive transfer of activated killer cells and interleukin-2.
Topalian SL; Rosenberg SA
Acta Haematol; 1987; 78 Suppl 1():75-6. PubMed ID: 3124451
[TBL] [Abstract][Full Text] [Related]
13. [Using LAK cells in the adoptive immunotherapy in cancers].
Urushizaki I
Rinsho Ketsueki; 1987 Oct; 28(10):1897-8. PubMed ID: 3502569
[No Abstract] [Full Text] [Related]
14. The adoptive immunotherapy of cancer using the transfer of activated lymphoid cells and interleukin-2.
Rosenberg SA
Semin Oncol; 1986 Jun; 13(2):200-6. PubMed ID: 3520827
[No Abstract] [Full Text] [Related]
15. Immunological effects of adoptive immunotherapy with IL-2: an overview.
Kradin R; Yamin R; Kurnick J
Pathol Immunopathol Res; 1988; 7(6):434-41. PubMed ID: 3070529
[No Abstract] [Full Text] [Related]
16. Fluctuations of plasma beta 2-microglobulin, soluble interleukin 2 receptor and interferon-gamma concentrations after adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells.
Giannella G; Pelosi-Testa E; Carlini P; Habetswallner D; Montesoro E; Camagna A; Calzini V; Ruggeri EM; Arena MG; Masciulli R
Immunobiology; 1989 Feb; 178(4-5):305-15. PubMed ID: 2497064
[TBL] [Abstract][Full Text] [Related]
17. The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Springer Semin Immunopathol; 1986; 9(1):51-71. PubMed ID: 3523804
[No Abstract] [Full Text] [Related]
18. [Regional transarterial infusion of autologous lymphokine-activated killer (LAK) cells for advanced renal cell carcinoma and its preliminary clinical result].
Hayakawa M; Masuda T; Higa I; Koyama Y; Hatano T; Oda M; Osawa A
Nihon Hinyokika Gakkai Zasshi; 1989 Jan; 80(1):28-34. PubMed ID: 2786104
[TBL] [Abstract][Full Text] [Related]
19. Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells.
Marcus SL; Dutcher JP; Paietta E; Ciobanu N; Strauman J; Wiernik PH; Hutner SH; Frank O; Baker H
Cancer Res; 1987 Aug; 47(15):4208-12. PubMed ID: 3496958
[TBL] [Abstract][Full Text] [Related]
20. [Study of head and neck cancer treatment by administration of autologous cytotoxic lymphocyte induced by stimulation with tumor cell--effect of adoptive immunotherapy by intra-arterial infusion of killer cells stimulated by autologous tumor in patients with maxillary carcinoma].
Eura M; Ikawa T; Ishikawa T; Fukiage T; Fukushima M; Samejima Y; Miyamura K
Nihon Jibiinkoka Gakkai Kaiho; 1988 Dec; 91(12):2069-78. PubMed ID: 3266241
[No Abstract] [Full Text] [Related]
[Next] [New Search]
